Today, Pfizer-BioNTech announced that the third dose of its COVID-19 vaccine has shown 95.6 percent efficacy compared to those who did not receive a booster. The results have been declared from a Phase 3 trial evaluating the efficacy and safety of a 30-µg booster dose, the same dosage strength as those in the primary series, of the mRNA-based Pfizer-BioNTech Covid-19 Vaccine.
Talking to the media, Pfizer CEO Albert Bourla mentioned that the results provide further evidence of the benefits of boosters as they aim to keep people well-protected against COVID-19. Sources revealed that over 10,000 individuals who had completed the primary two-dose series of the Pfizer Covid-19 vaccine participated in the booster dose trial.
In this, half of them received a 30-µg booster dose, while others received a placebo. After the test, the experts found five Covid-19 cases in the booster dose group while 109 cases in the placebo group.
Keeping in mind several subgroup analyses, the study suggests that booster dose efficacy was consistent irrespective of age, sex, race, ethnicity, or comorbid conditions. Reportedly, both Pfizer-BioNTech and Moderna Covid vaccines are the main vaccines of the US inoculation program.
Meanwhile, the third dose of the Pfizer Covid vaccine for emergency use has already been approved by the US Food and Drug Administration (FDA).